Rahul Gaurav1,2,3, Emina Arsovic1,4, Lydia Chougar1,4, Nadya Pyatigorskaya1,2,3,4, Marie Vidailhet2,3,5, and Stephane Lehericy1,2,3,4
1CENIR, ICM Paris, Paris, France, 2Paris Brain Institute (ICM), Sorbonne University, UPMC Univ Paris 06, Inserm U1127, CNRS UMR 7225, Paris, France, 3ICM Team “Movement Investigations and Therapeutics” (MOV’IT), Paris, France, 4Department of Neuroradiology, Pitié-Salpêtrière Hospital, AP-HP, Paris, France, 5Department of Neurology, APHP, Pitié-Salpêtrière Hospital, Paris, France
1CENIR, ICM Paris, Paris, France, 2Paris Brain Institute (ICM), Sorbonne University, UPMC Univ Paris 06, Inserm U1127, CNRS UMR 7225, Paris, France, 3ICM Team “Movement Investigations and Therapeutics” (MOV’IT), Paris, France, 4Department of Neuroradiology, Pitié-Salpêtrière Hospital, AP-HP, Paris, France, 5Department of Neurology, APHP, Pitié-Salpêtrière Hospital, Paris, France
Using neuromelanin-sensitive T1-weighted MRI, we found a significant decrease in substantia nigra pars compacta of atypical Parkinsonian disorders compared to healthy volunteers.
Figure 1: Substantia Nigra pars compacta regions of interest (left in yellow and right in pink) based on neuromelanin-sensitive imaging of a representative healthy volunteer.
Figure 2: Box plot of Substantia Nigra pars compacta volume in Atypical Parkinsonian along with healthy volunteers. HV is Healthy Volunteers, PD is Parkinson's Disease, PSP is Progressive supranuclear palsy, DCB is CorticoBasal Degeneration, MSA is Multiple System Atrophy, with its cerebellar (MSAc) and Parkinsonian (MSAp) subtypes, and DCL is dementia with Lewy body.
